Introduction {#S1}
============

Development of antibacterial resistance is considered one of the leading public health problems, since it has a significant impact on the economy worldwide. Since therapeutic options to treat infections are increasingly being limited due to antibacterial resistance, this escalates the morbidity and mortality associated with infectious diseases caused by bacteria \[[@B90]\]. ESKAPE pathogens are responsible for the majority of life-threatening nosocomial infections and are capable of "escaping" the biocidal action of antimicrobial agents ([@B69]). The term "ESKAPE" is an acronym for six bacterial pathogens associated with multidrug resistance: *Enterococcus faecium* (*E*. *faecium*), *Staphylococcus aureus* (*S*. *aureus*), *Klebsiella pneumoniae* (*K*. *pneumoniae*), *Acinetobacter baumannii* (*A*. *baumannii*), *Pseudomonas aeruginosa* (*P*. *aeruginosa*), and *Enterobacter spp.* ([@B61]). Multidrug-resistant (MDR) bacteria are resistant to more than one antimicrobial drug, and extensively drug-resistant (XDR) bacteria are types of drug-resistant organisms that are resistant to all, or almost all, approved antimicrobial agents ([@B52]). For these reasons, it is essential to design and engineer new promising classes of antibiotics ([@B26]).

The New Therapeutic Alternatives: Input From Recent Studies {#S2}
===========================================================

As we described above, the development of antimicrobial resistance represents a major threat to public health, and this has been echoed by different health organizations around the globe. Antimicrobial peptides (AMPs) and nanoparticles (NPs) and the design of novel combinatorial therapies are among the new promising alternatives to fight infections caused by MDR- and XDR-resistant bacteria.

Antimicrobial Peptides {#S2.SS1}
----------------------

Antimicrobial peptides are a highly diverse family of small proteins with a varying number of amino acids; they have also been referred to as cationic host defense peptides ([@B10]). A variety of synthetic AMPs have been synthesized in the laboratories, but there are also a wide diversity of AMPs produced by bacteria and yeast, in addition to those found naturally in animals and plants ([@B88]). AMPs have demonstrated to participate in a variety of biological activities, including as antimicrobial antiviral, antifungal, and anti-mitogenic agents, in addition to their antitumor and anti-inflammatory properties and their ability to act as immune modulators. Therefore, AMPs represent a potential alternative to replace a wide variety of commonly used drugs. Moreover, most of the available studies demonstrate that AMPs exhibit therapeutic activity in *in vitro* and *in vivo* models ([@B19]).

The use of AMPs alone or in combination with conventional drugs has proven effective in combating different infectious agents, mainly MDR bacteria ([@B97]). AMPs are promising potential candidates to counteract multiresistant pathogens since they possess many advantages: they display potent microbicidal activity in the micromolar range ([@B4]), they have demonstrated a rapid bacterial death action ([@B49]), and they have low resistance selection ([@B53]). Their mechanism of antibacterial action is multifunctional because it alters the cell membrane ([@B50]) and also attacks specific targets that take part in the development of different intracellular processes ([@B45]), such as inhibition of transcription, translation, protein synthesis, and bacterial cell wall formation ([@B63]). These general mechanisms of action of AMPs are displayed in [Figure 1A](#F1){ref-type="fig"}.

![Mechanism of antimicrobial action in bacteria: **(A)** General mechanisms of action of antimicrobial peptides (AMPs). AMPs act through different mechanisms ([@B45]) such as 1. Alteration in membrane integrity via electrostatic interaction with negatively charged cell membranes which kill cells, 2. Inhibition of DNA synthesis by (i) cross-linking with single- or double-stranded DNA, (ii) prevention of the DNA relaxation by inactivation of DNA topoisomerase I, and (iii) blocking of DNA replication by trapping the gyrase-DNA complex; and protein synthesis by (i) inhibition of protein translation by targeting the ribosomes, (ii) interrupting the protein-folding pathway, and (iii) rapid proteolytic activity causing the degradation of some DNA replication-associated proteins, leading to secondary inhibition of DNA synthesis, 3. Inhibition of bacterial cell wall formation by alteration of the alternating amino sugars in linear form that cross-link via peptide bridges to form the peptidoglycan layer, and 4. Inhibition of metabolic pathways by alteration of nucleic acid metabolism, including nucleotide transport and metabolism, nucleobase, nucleoside, and nucleotide interconversion. **(B)** Mechanisms for antimicrobial action of metal nanoparticles (MNPs). MNPs act via the following ([@B78]). 1. MNPs disturb cell membrane permeability by interfering with metabolic pathways and inducing changes in membrane shape and function. 2. When MNPs are in solution, metal ions are released in the environment surrounding. Metal ions generate reactive oxygen species (e.g., oxygen ions and hydroxyl radicals) and induce oxidative stress in bacteria. Oxidative stress is a key contributor in altering the bacterial membrane permeability and thus can damage cell membranes. Also, metal ions may cause cell structural changes and aberrant enzyme activities, which perturb normal physiological processes. 3. Interaction with sulfur- and phosphorous-containing compounds such as DNA, which prevent DNA from unwinding and transcription.](fmicb-11-01669-g001){#F1}

One AMP of particular interest is human cathelicidin peptide (LL-37), which has been reported to have wound-healing effects on the host in addition to exhibiting antimicrobial and anti-biofilm activity against a variety of Gram-positive and Gram-negative human pathogens ([@B20]). LL-37 and its derivatives are considered excellent candidates as antimicrobial therapeutic agents and have been the subject of many studies ([@B21]; [@B42]; [@B16]). Especially, in 2018, De Breij et al. synthesized an LL-37 derivative (SAAP-148), with potent antimicrobial activities, by replacing an amino acid from the terminal carbon of the LL-37 chain. This LL-37 derivative exhibited a minimum inhibitory concentration \[MIC\] between 0.4 and 12.8 μM against various ESKAPE pathogenic bacteria (e.g., *E. faecium*, *S. aureus*, *K. pneumoniae*, *A. baumannii*, *P. aeruginosa*, and *Enterobacter* species) without selection of resistance. Furthermore, this AMP derivative showed anti-biofilm activity against *S. aureus*, *A. baumannii*, and *P. aeruginosa* ([@B16]).

Colistin is another important peptide antibiotic (produced *Bacillus polymyxa* var. *colistinus*) used as a last-resort drug to treat MDR infections ([@B66]). It has emerged as an important agent in the treatment of Gram-negative bacterial infections, especially those caused by MDR pathogens in hospitalized patients ([@B15]). Notably, two new colistin-derived AMPs (AA139 and SET-M33), with a mechanism similar to colistin, are in development and have shown excellent therapeutic potential both *in vitro* against MDR bacteria and in *in vivo* infection models ([@B85]).

The main limiting factor for the systemic use of AMPs is their sensitivity to proteolytic digestion in different body fluids (e.g., intestinal mucosa, gastrointestinal tract, and blood plasma), which directly affect both their *in vivo* stability and their pharmacokinetic profile ([@B57]; [@B82]). Therefore, the search for new AMPs continues, particularly in a new class of peptides with high specificity and potency, known as "selectively targeted AMPs" (STAMPs), which show increased sensitivity to specific pathogens, demonstrating a significant increase in their bactericidal capacity without direct effects on the microbiota ([@B14]). The STAMP technology requires two functionally independent peptide domains integrated through a small linker. One peptide domain serves as the killing AMP moiety and the other peptide domain consisting of a high-affinity binding peptide which functions as a targeting moiety ([@B4]). These properties increase the binding to the surface of a targeted pathogen by enhancing the local concentration of the AMP and thus lead to improve bactericidal efficiency ([@B75]). In recent years, several new and promising STEMs have been developed against *Streptococcus mutans* ([@B35]), *Pseudomonas aeruginosa*, and *Streptococcus mutants* together ([@B34]), methicillin-resistant *Staphylococcus aureus* ([@B55]), *Enterococcus faecalis* ([@B94]), and clinical isolates (*Pseudomonas aeruginosa*; [@B23]). Nonetheless, more preclinical and clinical research is needed in the development of targeted antimicrobial therapy.

Metal Nanoparticles {#S2.SS2}
-------------------

An additional alternative to fighting infections caused by antibiotic-resistant bacteria is the development of NPs since it has been amply reported that metal nanoparticles (MNPs) have antibacterial activity against ESKAPE pathogens ([@B89]; [@B47]). Some of the mechanisms of the antimicrobial mode of action of MNPs are summarized in [Figure 1B](#F1){ref-type="fig"}. In the search for new antimicrobials to treat the ESKAPE pathogens, silver has been highlighted as a potential candidate to treat infectious diseases ([@B11]). Silver nanoparticles (AgNPs) possess antimicrobial activity, and they act by disturbing cell membrane permeability, interacting with sulfur- and phosphorous-containing compounds including DNA, in addition to their ability to release silver ions, contributing to the antibacterial effect ([@B59]; [@B60]). Gold (Au) nanoparticles have also been reported as effective antibacterial agents for antibiotic-resistant bacterial strains such as *S*. *aureus*, *E*. *faecium*, *Enterococcus faecalis* (*E*. *faecium*), *Escherichia coli* (*E*. *coli*), *Vibrio cholerae* (*V*. *cholerae*), *Salmonella typhimurium* (*S*. *typhimurium*), and *Salmonella dysenteriae* (*S*. *dysenteriae*; [@B44]).

Among metal oxide nanoparticles, zinc oxide (ZnO) nanoparticles have shown antimicrobial activity against both Gram-negative and Gram-positive bacteria, including *Bacillus subtilis* (*B*. *subtilis*), *S*. *aureus*, *E*. *coli*, *P*. *aeruginosa*, and *A*. *baumannii* ([@B32]; [@B84]). On the other hand, among photocatalytic nanoparticles, titanium dioxide (TiO~2~) NPs have been extensively studied due to their antimicrobial activity ([@B31]). Several studies have reported the antimicrobial activity of TiO~2~ NPs against methicillin-resistant *S*. *aureus* and MDR *E*. *coli* ([@B37]; [@B54]; [@B17]).

Despite the advantages that nanoparticles offer, such as a broad therapeutic index, controlled drug release, less prone to bacterial resistance, and fewer side effects than chemical antimicrobials ([@B47]), to treat infections caused by the ESKAPE pathogens, there are still challenges remaining to be tackled such as improvement of physicochemical properties, better pharmacokinetic profiles, and comprehensive studies on long-term exposure to humans. In terms of design and application, there is a particular interest in the generation of nanohybrids combining different metals with different antimicrobial and sensitizer agents ([@B96]; [@B91]). Metal nanoparticle-based compounds (alone or in combination with other antimicrobial agents) provide promising alternatives to combat the development of antibacterial resistance ([@B78]). Therefore, it is imperative to develop a comprehensive understanding of the mechanisms of action responsible for the bactericidal properties as well as the identification of the most promising antimicrobial agents for future clinical translation.

Combinatorial Treatments {#S2.SS3}
------------------------

The strategies to reduce antibiotic resistance include the limited use of antibiotics and the application of more effective antibacterial therapies. Because the time of exposure to antibiotics correlates with the development of resistance ([@B3]), it is necessary to use drugs with a broad spectrum of action and pharmacokinetic properties that facilitate their rapid access to the target site ([@B43]). However, most of the available treatments do not have all these characteristics, so an alternative option is the use of combination therapies, which can lead to a synergistic and more effective response ([@B48]). It has been shown that the combination of drugs leads to a considerably more potent effect, compared to the individual drug ([@B83]; [@B56]). [Figure 2](#F2){ref-type="fig"} displays the disadvantages of using single drugs ([Figure 2A](#F2){ref-type="fig"}) and the advantages of using combinatorial treatments ([Figure 2B](#F2){ref-type="fig"}).

![Antimicrobial treatment strategies: **(A)** disadvantages of using single drugs and **(B)** advantages of using combinatorial treatments. The advantage of using combinatorial treatments of synergistic drug pairs provides the opportunity to lower the dosage of the individual agents, thereby reducing toxicity while maintaining the wanted effect on bacteria. Moreover, a synergistic response can occur because of complementary drug action (multiple targets sites on the same protein or pathway are hit; [@B68]). By combining two drugs that achieve the same effect through different mechanisms of action, the development of resistance to a single drug in the combination may be less likely to occur, and when it does occur, it may have a lower impact on the therapeutic outcome ([@B71]). Finally, the use of more than one agent broadens the antibacterial spectrum of the empirical therapy and thus ensures that at least one agent will cover the infecting organism ([@B33]).](fmicb-11-01669-g002){#F2}

### Antimicrobial Peptide-Based Combinatorial Treatments {#S2.SS3.SSS1}

Combinations of AMPs with antibiotics have been reported to show synergistic effects in the treatment of bacterial infections. The mechanism of antibacterial action in these combinations involves the disruption of the outer membrane ([@B13]). Moreover, the use of AMPs in combinatorial treatments has certain advantages over their use as a single treatment since it has been observed that in combinatorial treatments, AMPs work as enhancers of the antimicrobial effects. This characteristic allows the reduction of their dose, and it also unlocks the bactericidal application of molecules with low molecular weight, which typically do not exhibit antimicrobial properties ([@B80]).

Recent studies have demonstrated the synergistic activity of antibiotics combined with AMPs. [@B1] reported the synergism and other drug interactions between melittin, a cationic amphipathic peptide, and antibiotics such as doripenem, doxycycline, colistin, and ceftazidime, against MDR isolates of *A*. *baumannii* and *P*. *aeruginosa*. Likewise, combinatorial treatments of conventional antibiotics with new synthetic peptides inspired by human cationic peptides LL-37 and thrombocidin-1 (TC-1) have shown synergistic activity against *S*. *aureus* (antibacterial and anti-biofilm activity; [@B40]). In addition, the synergistic activity of 30 short AMPs combined with several conventional antibiotics such as beta-lactam antibiotics, cephalosporins, aminoglycosides, and quinolones was tested against an MDR *P*. *aeruginosa* isolate (PA910; [@B74]). Several combinations between peptides, polymyxin B, erythromycin, and tetracycline, as well as novel variants of indolicidin were found to be synergistic. Furthermore, the results showed that a single amino acid substitution within the peptides can have a powerful effect on the ability to synergize, which represents an opportunity to design treatment strategies based on synergistic interactions ([@B74]).

### Metal Nanoparticle-Based Combinatorial Treatments {#S2.SS3.SSS2}

Metal nanoparticles should be considered as an attractive alternative to potentiate the antimicrobial effect of old and current antibiotics, since they have a high tendency to act synergistically when combined with a wide variety of antibiotics ([@B6]). This, in addition to the increased biocompatibility achieved by synthesizing them through green chemistry, allows considering the use of MNPs as adjuvant agents for the treatment of infectious diseases ([@B73]).

In the past years, there has been a marked increase in the use of biopolymers (e.g., proteins, nucleic acids, and polysaccharide) as capping agents to functionalize and stabilize MNPs ([@B79]). Exopolysaccharides are biocompatible and eco-friendly biomolecules; therefore, they can be used in the synthesis of MNPs ([@B25]). Recently, a silver-based nanobiocomposite was synthesized using an exopolysaccharide produced by *Rhodotorula mucilaginosa* UANL-001L (EPS). The results showed an increased antibacterial and anti-biofilm activity of this nanobiocomposite against pathogens of clinical relevance ([@B87]). Moreover, nanocomposites have been synthesized through green chemistry, such as zinc (Zn) and nickel (Ni) MNPs capped with EPS as capping agents, and they have displayed interesting antimicrobial properties as well. Ni-EPS nanoparticles exhibited both antimicrobial and anti-biofilm activity against resistant MDR strains of *S*. *aureus* and *P*. *aeruginosa*. Furthermore, Zn-EPS nanoparticles showed antimicrobial activity for treatments against MDR *S*. *aureus* and *P*. *aeruginosa* ([@B28]).

Among the most studied nanomaterials are silver nanoparticles due to their antimicrobial activity against Gram-positive and Gram-negative bacteria. They can be used in combinatorial treatments with currently used antibiotics for enhanced antimicrobial activity ([@B77]; [@B41]; [@B64]; [@B81]; [@B67]; [@B51]; [@B70]; [@B86]). Nonetheless, some other MNPs such as gold ([@B24]; [@B38]; [@B2]; [@B5]; [@B46]; [@B65]; [@B95]), copper ([@B39]; [@B92]; [@B62]; [@B76]), and zinc ([@B7]; [@B9]) have been used in combination with a variety of antibiotic families to enhance bactericidal efficacy.

Some other interesting studies of silver-based nanomaterials have been reported. A novel silver-microfibrillated cellulose biocomposite has been synthesized, and its antimicrobial activity was determined against relevant clinical strains. The results showed that this biocomposite has antimicrobial activity against Gram-negative and Gram-positive bacteria so that it could be applied in the development of biocompatible biomedical devices ([@B29]). Another promising approach toward the development of new antimicrobial combinatorial treatments is the use of transition metals, since they exhibit rapid and significant toxicity, at low concentrations, in different bacterial strains. Garza-Cervantes et al. evaluated the synergistic antimicrobial effects of silver/transition-metal combinatorial treatments. Their results showed combinatorial treatments that exhibited synergism (Ag--Zn, Ag--Co, Ag--Cd, Ag--Ni, and Ag--Cu) since their antimicrobial effects are increased up to 8-fold, compared to the effects observed for the treatments with the individual metals ([@B27]). Furthermore, Montelongo-Peralta et al. reported synergism between transition metals and antibiotics used to treat first-line drug-resistant strains of *Mycobacterium tuberculosis* (*M*. *tuberculosis*). Combinatorial treatments composed of isoniazid/silver exhibited a synergistic bactericidal effect in an isoniazid-resistant clinical strain of *M*. *tuberculosis* ([@B58]).

Moreover, a previous study showed the ability of silver to potentiate the activity of a broad range of antibiotics against Gram-negative bacteria, as well as to restore antibiotic susceptibility (re-sensitizing) to a resistant bacterial strain ([@B60]). Recently, a group of researchers achieved to re-sensitize antibiotic-resistant *E*. *coli* using transition-metal micronutrients (Cu2+, Zn2+, Co2+, Cd2+, and Ni2+) combined with antibiotics (ampicillin and kanamycin). These combinatorial treatments showed a therapeutic activity and no toxicological effects in a murine topical infection model caused by antibiotic-resistant strains ([@B30]). The above data therefore strongly suggest that combination therapies are a potential strategy in the development of new treatments against infectious diseases.

The search for a new generation of antimicrobials to mitigate the spread of antibiotic resistance is urgent ([@B18]). Current research and technology developments have promoted the improvement of antimicrobial agents that selectively target a target site (e.g., a gene, a cellular process, or a specific pathogen; [@B18]; [@B36]). AMPs and MNPs exemplify a novel approach for treating infectious diseases. Nonetheless, the combinatorial treatments are considered as an excellent option for designing and developing next-generation antibacterial agents. As summary, [Table 1](#T1){ref-type="table"} describes the mechanism of action, tested bacterial strains, advantages and disadvantages of AMPs, MNPs, and combinatorial treatments.

###### 

Antimicrobial peptides, metal nanoparticles, and combinatorial treatments: mechanism of action, tested bacterial strains, advantages, and disadvantages.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                  **Mechanism of action**                                                  **Tested bacterial strains**                                                                                                                                                                                                                                                                        **Advantages**                                                    **Disadvantages**
  ------------------------------- ------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------- --------------------------------------------------------------------------
  Antimicrobial peptides (AMPs)   1\. Alteration in membrane integrity.\                                   *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumanii*, *Pseudomonas aeruginosa*, *Enterobacter spp.*, multidrug-resistant strains.                                                                                                                     1\. Show potent microbicidal activity in the micromolar range.\   1\. High sensitivity to proteolytic digestion in different body fluids.\
                                  2. Inhibition of DNA and protein synthesis.\                                                                                                                                                                                                                                                                                                                                 2. Rapid bacterial death action.\                                 2. Low *in vivo* stability.\
                                  3. Inhibition of bacterial cell wall formation.\                                                                                                                                                                                                                                                                                                                             3. Low resistance selection.                                      3. Reduced pharmacokinetic profile.
                                  4. Inhibition of metabolic pathways.                                                                                                                                                                                                                                                                                                                                                                                                           

  Metal nanoparticles (MNPs)      1\. Disruption of cell membrane and increased permeability.\             *Enterococcus faecium*, *Enterococcus faecalis, Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumanii*, *Pseudomonas aeruginosa*, *Escherichia coli*, *Salmonella typhimurium*, *Salmonella dysenteriae*, *Vibrio cholerae*, *Bacillus subtilis*, multidrug-resistant strains.   1\. Broad therapeutic index.\                                     1\. Need to improve metal ions release from MNPs.\
                                  2. Releasing metal ions.\                                                                                                                                                                                                                                                                                                                                                    2. Controlled drug release.\                                      2. Moderate stability in biological fluids.\
                                  3. Interaction with DNA                                                                                                                                                                                                                                                                                                                                                      3. Less prone to bacterial resistance.\                           3. Reduced long-term toxicity studies.
                                                                                                                                                                                                                                                                                                                                                                                                               4. Fewer side effects than chemical antimicrobials.               

  Combinatorial treatments        1\. Synergistic response.\                                               *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumanii*, *Pseudomonas aeruginosa*, *Escherichia coli Mycobacterium tuberculosis* multidrug-resistant strains.                                                                                            1\. Require lower dose than a single drug.\                       1\. Physical-chemical compatibility among antimicrobial agents.\
                                  2. Multiple cellular targets for antimicrobial action.\                                                                                                                                                                                                                                                                                                                      2. Reduced toxicity.\                                             2. Possible pharmacokinetic and pharmacodynamic interactions.
                                  3. Combination of bactericidal and bacteriostatic mechanism of action.                                                                                                                                                                                                                                                                                                       3. Synergisms and more effective response.\                       
                                                                                                                                                                                                                                                                                                                                                                                                               4. Decrease the probability of resistance evolution.\             
                                                                                                                                                                                                                                                                                                                                                                                                               5. Better efficacy against multidrug-resistant bacteria.          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The selection of appropriate combinatorial treatment is critical for the successful prevention of infections ([@B8]). The most important challenges include (i) selection of agents with ideal physical--chemical properties (hydrosolubility and chemical stability in biological fluids; [@B22]), (ii) selection of antimicrobials that display appropriate pharmacokinetics and pharmacodynamics properties ([@B72]), (iii) selection of biocompatible capping agents or biopolymer-based materials that enable drug release ([@B12]), and (iv) development of a process that ensures the stability and does not compromise the performance of the combination therapy formulation as a whole ([@B93]). Therefore, the design of combinatorial treatment provides a pathway to develop antimicrobial therapeutics with broad-spectrum antimicrobial activity, bactericidal instead of bacteriostatic mechanism of action, and better efficacy against MDR bacteria.
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